VMD's main competitors are Lincare (owned by Linde AG) and Apria Healthcare (APR).
APR's top line YoY growth this year is only 4%, see:
https://www.globenewswire.com/news-release/2021/11/04/2328043/4031/en/Apria-Announces-Financial-Results-for-Third-Quarter-2021.html
For comparison, VMD's top line YoY growth for its core business this year is
12%:
"Net revenues attributable to the Company's core business for the quarter ended September 30, 2021 were $27.8 million, a new Company record, and an increase of $2.9 million, or 12%, over core business revenues reported for the comparable quarter ended September 30, 2020."
APR was acquired just one month ago for a total transaction value of $1.6 billion:
https://www.pymnts.com/acquisitions/2022/healthcare-firm-owens-minor-buys-apria-for-1-6b/
According to APR's guidance, adj. EBITDA this year is about $230 million.
Therefore, APR with only 4% YoY growth was acquired for 7 times its adj. EBITDA.
For comparison, VMD's adj. EBITDA this year will be about $28-$29 million.
VMD's Enterprise Value at US$4 per share is $140 million.
Therefore, VMD has 12% YoY growth (VMD reports much stronger growth than APR) but its Enterprise Value at US$4 per share is only 4.5 times its adj. EBITDA!!!